PROCEPT BioRobotics (PRCT) Projected to Post Earnings on Thursday

PROCEPT BioRobotics (NASDAQ:PRCT) is projected to release its Q1 2026 results before the market opens on Thursday, April 23rd. Analysts expect PROCEPT BioRobotics to post earnings of ($0.5528) per share and revenue of $80.6530 million for the quarter. Individuals may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, April 29, 2026 at 4:30 PM ET.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its earnings results on Wednesday, February 25th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.21). The business had revenue of $76.38 million during the quarter, compared to the consensus estimate of $93.70 million. PROCEPT BioRobotics had a negative return on equity of 25.13% and a negative net margin of 31.02%.The business’s revenue was up 11.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.35) earnings per share. On average, analysts expect PROCEPT BioRobotics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

PROCEPT BioRobotics Stock Performance

PRCT stock opened at $25.67 on Thursday. The company has a quick ratio of 5.77, a current ratio of 6.85 and a debt-to-equity ratio of 0.14. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of -15.01 and a beta of 0.94. PROCEPT BioRobotics has a 12 month low of $19.35 and a 12 month high of $66.85. The firm has a 50 day moving average of $26.05 and a two-hundred day moving average of $30.31.

Wall Street Analysts Forecast Growth

PRCT has been the topic of several recent research reports. Wells Fargo & Company cut their target price on PROCEPT BioRobotics from $51.00 to $34.00 and set an “overweight” rating on the stock in a report on Thursday, February 26th. Wall Street Zen lowered PROCEPT BioRobotics from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Truist Financial cut their target price on PROCEPT BioRobotics from $47.00 to $30.00 and set a “buy” rating on the stock in a report on Friday, February 27th. Weiss Ratings restated a “sell (e+)” rating on shares of PROCEPT BioRobotics in a report on Thursday, January 22nd. Finally, Leerink Partners cut their target price on PROCEPT BioRobotics from $55.00 to $30.00 and set an “outperform” rating on the stock in a report on Thursday, February 26th. Eight analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $40.82.

Insider Buying and Selling at PROCEPT BioRobotics

In related news, Director Antal Rohit Desai bought 167,246 shares of the business’s stock in a transaction on Thursday, March 5th. The shares were bought at an average cost of $25.58 per share, for a total transaction of $4,278,152.68. Following the completion of the acquisition, the director directly owned 167,246 shares in the company, valued at approximately $4,278,152.68. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Kevin Waters sold 6,721 shares of the firm’s stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $23.70, for a total value of $159,287.70. Following the transaction, the executive vice president owned 152,264 shares in the company, valued at approximately $3,608,656.80. This trade represents a 4.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have purchased 426,262 shares of company stock worth $10,483,091 and have sold 23,229 shares worth $573,466. Corporate insiders own 6.60% of the company’s stock.

Hedge Funds Weigh In On PROCEPT BioRobotics

A number of institutional investors have recently made changes to their positions in PRCT. AQR Capital Management LLC increased its stake in shares of PROCEPT BioRobotics by 7.3% in the first quarter. AQR Capital Management LLC now owns 18,892 shares of the company’s stock worth $1,101,000 after purchasing an additional 1,286 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of PROCEPT BioRobotics by 9.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 153,158 shares of the company’s stock worth $8,923,000 after purchasing an additional 13,767 shares during the period. Intech Investment Management LLC increased its stake in shares of PROCEPT BioRobotics by 54.4% in the first quarter. Intech Investment Management LLC now owns 28,389 shares of the company’s stock worth $1,654,000 after purchasing an additional 10,002 shares during the period. Prudential Financial Inc. increased its stake in shares of PROCEPT BioRobotics by 100.4% in the second quarter. Prudential Financial Inc. now owns 6,815 shares of the company’s stock worth $393,000 after purchasing an additional 3,415 shares during the period. Finally, State Street Corp increased its stake in shares of PROCEPT BioRobotics by 6.9% in the second quarter. State Street Corp now owns 1,269,110 shares of the company’s stock worth $73,101,000 after purchasing an additional 81,849 shares during the period. 89.46% of the stock is currently owned by institutional investors.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.